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a variable phenotype, and gender development is very difficult to predict.
Novel Insights
•	 46,XY	patients	with	17β-hydroxysteroid	dehydrogenase	deficiency	have	testosterone	levels	at	the	time	
of puberty that mainly depend on the underlying mutation of the HSD17B3 gene. These mutations 
may be predictors of pubertal development and hence of gender development.
DOI: 10.1159/000453613
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Abstract
Background: 17β-hydroxysteroid dehydrogenase (17β-HSD) 
type 3 deficiency is an autosomal recessive disorder with di-
minished testosterone synthesis and consequently under-
androgenisation. 46,XY patients with 17β-HSD type 3 defi-
ciency are often assigned a female sex at birth but have a 
high virilisation potential at the time of puberty. Methods: 
We studied four 46,XY patients with 17β-HSD type 3 defi-
ciency at puberty with regard to the underlying mutations, 
the hormone values, and the clinical findings. Results: Three 
patients were initially assigned a female sex and 1 was as-
signed a male sex. All had relevant mutations in the HSD17B3 
gene. The 2 patients with deleterious mutations had lower 
testosterone values at the time of puberty than the patients 
with possible residual activity of 17β-HSD type 3. One of the 
latter patients changed to male gender. Conclusion: All 4 
patients with 17β-HSD type 3 deficiency synthesized rele-
vant amounts (>0.7 µg/L) of testosterone at puberty, which 
lead to variable androgenisation. In patients with presum-
able residual activity of the mutated enzyme, testosterone 
values in the male reference range can be achieved, thereby 
inducing male pubertal development. These patients should 
possibly be assigned a male sex. Any surgical intervention 
should be avoided until the patients are old enough to con-
sider their options of medical and surgical intervention.
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Introduction
Differences or disorders of sex development (DSD) 
constitute an array of mostly hereditary conditions with 
a divergence of chromosomal, gonadal, and phenotypic 
sex. While some causes of DSD are well described, others 
remain elusive with regard to the underlying genetic ab-
normality. Even in those cases, in which the biochemical 
and genetic conditions are well described, the decision-
making process of sex assignment and the overall man-
agement of the affected individuals are difficult [1]. 
17β-hydroxysteroid	 dehydrogenase	 (17β-HSD)	 defi-
ciency	is	a	disorder	affecting	46,XY	individuals,	leading	
to a moderate to severe underandrogenisation in utero 
due to defective testosterone synthesis. It is an autosomal 
recessive disorder with mutations in the HSD17B3 gene 
on chromosome 9q22 coding for the isoenzyme type 3 
within	the	family	of	17β-HSDs	[2, 3].	17β-HSD	type	3	is	
highly expressed in the developing testes, leading to con-
version	 of	 Δ4-androstenedione	 to	 testosterone,	 which	
acts locally due to high intratesticular concentrations and 
is also released into the periphery for further endocrine 
action [4].	The	isoenzyme	17β-HSD	type	5	is	able	to	con-
tribute to conversion from androstenedione to testoster-
one especially postnatally and at the time of puberty [5]. 
Therefore,	 46,XY	 individuals	with	 17β-HSD	 type	 3	
deficiency are often born with female-appearing exter-
nal genitalia with only slight androgenisation [6–9]. The 
development of prostate, seminal vesicles, and epididy-
mis is variable. The testes are localized in the inguinal 
canal or even abdominal. The children are often as-
signed a female sex and the diagnosis may be missed 
until childhood when hernias may occur or even be de-
ferred until adolescence when female pubertal develop-
ment is lacking. Instead, at puberty a massive surge of 
androstenedione is observed with variable conversion to 
testosterone [10]. The patients may demonstrate en-
largement of the phallic structures, deepening of the 
voice, male body appearance and male secondary hair 
growth. The virilisation has been attributed to 3 pecu-
liarities. First, androstenedione is a weak androgen act-
ing through the androgen receptor, thereby inducing 
androgenic effects itself [11]. Second, testosterone syn-
thesis occurs through an alternative pathway utilizing 
mainly	 17β-HSD	 type	 5.	 It	 has	 recently	 been	 demon-
strated	that	17β-HSD	type	5	is	expressed	in	Leydig	cells	
and	that	therefore	testosterone	in	17β-HSD	deficiency	is	
of testicular origin [4,	5]. Third, residual activity of the 
mutated	17β-HSD	type	3	enzyme	may	contribute	 to	a	
pubertal testosterone synthesis [2].
Additionally, patient descriptions indicate a high vari-
ability	 of	 testosterone	 levels	 in	 pubertal	 46,XY	 subjects	
with	 17β-HSD	deficiency	 [12]. It remains unclear if the 
testosterone synthesis contributes to gender identity in 
these individuals, but a gender change has been reported 
frequently	in	17β-HSD	deficiency	and	also	in	5α-reductase	
deficiency, especially in clusters from developing countries 
[12–15]. In Western countries, gonadectomy is often per-
formed	early	in	life	and	the	46,XY	children	with	17β-HSD	
deficiency are raised in the female gender [16,	17]. The dif-
ficult and often arbitrary mode of sex assignment has been 
discussed in an earlier report by us [18] and others [15, 16].
Here	we	describe	four	46,XY	patients	with	17β-HSD	
deficiency seen at the University of Lübeck for assessment 
at the time of puberty with their gonads in situ. Genetic 
and endocrine findings as well as gender role and conse-
quently sex assignment are discussed.
Patients and Methods
Patients
Patient 1 came to our attention at the age of 15;11 years. She 
reported that she had noticed that pubertal development had not 
proceeded	 in	a	 female	 fashion	 for	4	years.	She	had	observed	no	
breast development, instead the clitoris had grown. Her father re-
ported that a hernia repair had been performed at the age of 2 years 
and testes had been found, but no consequences had been sug-
gested.	Prior	 to	presenting	at	 the	University	of	Lübeck,	a	46,XY	
karyotype had been analysed. To prevent acne and to promote 
breast development, she had been put on a therapy with cyproter-
one acetate and estradiol valerate. Physical examination in our in-
stitution showed a slim individual with moderate to severe acne in 
the face, a hoarse voice, breast development corresponding to Tan-
ner	stage	B2,	pubic	hair	corresponding	to	Tanner	stage	PH4,	and	
a clitoris of 5 cm in length. A thorough investigation in general 
anaesthesia showed a short, female-appearing urethra and a vagina 
of 5 cm in length. The gonads were located in the inguinal canal. 
Laboratory investigations for endocrine values and molecular ge-
netic analysis of the HSD17B3 gene were initiated. 
At psychological assessment the patient initially described am-
bivalence. On the one hand, the patient wished to remain in the 
female gender; on the other hand, she expressed the burden of se-
crecy and shame within the family and the bearing of the surgical 
intervention. A consensus conference at our centre favoured re-
moval of the gonads, which was discussed thoroughly with the 
patient who then consented to the gonadectomy. The gonads his-
tologically demonstrated some interstitial fibrosis and no sper-
matogenesis, but otherwise normal testicular appearance. After 
gonadectomy, the testosterone level fell immediately and the pa-
tient was put on estradiol valerate 2 mg daily for substitution [5].
Patient 2 came to medical attention at the age of 16;6 years for 
primary amenorrhea at another institution. An elevated testoster-
one level was found, and on ultrasound a uterus was not detected. 
Chromosomal	analysis	 revealed	a	46,XY	karyotype,	 and	 the	pa-























   
   
   
   
   
   
   























Horm Res Paediatr 2017;87:354–358356
DOI: 10.1159/000453613
17;9	years	old,	was	suffering	from	obesity,	and	had	slight	acne	in	
the face. She had pseudogynecomastia, but the glandular breast 
tissue was only 2–3 cm in diameter. Her pubic hair was corre-
sponding to Tanner stage PH5. On gynaecologic examination, her 
labia minora were slightly fused in the dorsal part and the clitoris 
was enlarged to 2.5 cm. The vagina was short with a length of 3 cm. 
Laboratory and genetic analyses confirmed the diagnosis of 
17β-HSD	type	3	deficiency.	The	patient	opted	for	staying	in	the	
female gender and proceeded to gonadectomy at an outside hos-
pital. The gonads were localized at the inner inguinal canal and 
demonstrated apparently histologically normal testicular tissue.
Patient 3 came to initial attention at the age of 13;6 years. She 
had	been	raised	female	without	major	peculiarities.	At	the	time	of	
puberty, virilisation was marked. At the initial presentation at the 
Department	of	Paediatrics	at	the	University	of	Kiel,	a	46,XY	karyo-
type was determined and further laboratory and genetic testing 
was	initiated,	which	proved	17β-HSD	type	3	deficiency.	The	pa-
tient voiced strongly that since the age of 11 years, a male identity 
had	been	felt.	On	physical	examination	at	 the	age	of	14;1	years,	
gender change to male had already been pursued after thorough 
evaluation by experts from sexual medicine and psychology. At 
this time, the physical appearance was male without any breast de-
velopment;	 pubic	 hair	 corresponded	 to	Tanner	 stage	 PH4.	The	
phallus was short and bent due to severe chorda, but on ultrasound 
erectile tissue was present. Several surgical procedures were per-
formed to move the inguinal testes into the scrotum and to per-
form straightening of the penis with build-up of a neo-urethra. 
Patient	4	has	been	described	earlier	in	detail	in	his	childhood	
appearance [18]. He and his younger sibling had been born with 
ambiguous	genitalia.	Genetic	analysis	revealed	a	46,XY	karyotype	
in	 both	 individuals	 and	 later	 17β-HSD	 type	 3	 deficiency	 was	
proved	by	mutation	analysis.	While	patient	4	was	raised	male,	the	
younger sibling was raised female and the gonads had been re-
moved.	Patient	4	underwent	several	hypospadias	repair	operations	
at outside hospitals and presented again at the age of 16;6 years at 
the University of Lübeck. He reported to have gone through spon-
taneous puberty without hormone supplementation. He had a 
muscular male habitus and shaved 2 times weekly. Penile length 
was 5 cm with a diameter of 2.5 cm and normal urethral opening 
after hypospadias repair. Pubic hair corresponded to Tanner stage 
PH5.	He	reported	erections	and	ejaculations	but	did	not	consent	
to sperm analysis. Testicular volume was 15 mL and both testes 
were in the scrotum. Laboratory investigations were performed.
Except	for	patient	4,	molecular	genetic	investigations	for	car-
rier status of the HSD17B3 mutations were not performed in the 
parents. All patients and legal guardians consented to the use of 
medical data for scientific purposes.
DNA Analysis
DNA was extracted from peripheral blood cells by standard 
procedures. The HSD17B3 gene was amplified by PCR in 11 parts 
spanning the individual exons including the intron-exon boundar-
ies. All amplicons were directly sequenced, and sequences were 
analysed on an ABI Applied 3130/Genetic Analyser. After the 
analysis, finished samples were then integrated using SeqScape 
(version 2.5) software (ABI).
Hormone Analysis
Blood	was	drawn	at	the	age	of	15;11–17;11	years,	when	the	pa-
tients were presumably advanced in pubertal development. LH 
and FSH were measured by standard assays on an Elecsys 2010-3 
(Roche, Germany). Androstenedione and testosterone were either 
measured by immunometric analysis (Immulite 2000, Siemens, 
Germany, for androstenedione, and Elecsys 2010-3, Roche, for tes-
tosterone) or by radioimmunoassay after extraction (patient 3) or 
by LC-MSMS as described by Kulle et al. [19]	in	patient	4.	
Results
In	all	4	patients	a	relevant	mutation	in	the	HSD17B3 
gene was found. Patients 1 and 2 carried the common 
splice-site	mutation	c.277+4	A>T	in	a	homozygous	fash-
ion. This mutation was initially described by Boehmer et 
al. [7]	as	c.325+4	A>T	and	is	known	to	disrupt	the	func-
tion	of	17β-HSD	type	3	completely.	Patient	3	carried	this	
mutation in a heterozygote fashion and a second hetero-
zygous mutation, p.N130S, which was initially described 
by Moghrabi et al. [20]. These authors found that the 
p.N130S mutation led to a severe albeit not complete loss 
of	enzymatic	activity.	Patient	4	carried	this	p.N130S	mu-
tation in a heterozygote fashion and an additional hetero-
zygote well-described mutation, p.R80Q, which has re-
sidual enzymatic activity [2, 12].
The hormone values and the adult male reference 
ranges are shown in Table 1. All patients had slightly el-
evated LH levels, pointing towards hypergonadotrophic 
hypogonadism. However, the testosterone levels were 
quite variable. While the testosterone levels were below 
the adult male reference range in patients 1 and 2, the val-
ues	in	patients	3	and	4	were	significantly	higher	and	in	the	
lower- to mid-adult reference range. Interestingly, FSH 
levels were also highly variable, and especially in patient 
3 highly elevated, pointing towards a common testicular 
failure. In all patients, the testosterone to androstenedi-





tosterone	 biosynthesis	 leading	 to	 46,XY	DSD.	 The	 pa-
tients described here fit well with the previous clinical de-
scriptions of this condition. In all patients, a relevant mu-
tation in the HSD17B3 gene was detected. Two patients 
had	 the	common	c.277+4	A>T	mutation	 in	a	homozy-
gous fashion, which seems to be prevalent in European 
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levels were measurable and above the female reference 
range	 for	 age	 (0.2–0.37	 µg/L),	 pointing	 towards	 an	 in-
creased testosterone synthesis. In patient 1 this may be 
due to the increased androstenedione value; however, in 
patient 2 the peripheral androstenedione value was with-
in	 the	usual	 female	 reference	 range	 (1.0–4.95	µg/L,	 for	
Immulite 2000, women Tanner stage 5). 
In	patients	3	and	4,	two	relevant	heterozygous	muta-
tions in the HSD17B3 gene were present. According to 
Moghrabi et al. [20], the p.N130S exchange leads to a se-
vere functional deficit of the mutated enzyme, while the 
p.R80Q enzyme has even more residual function [2] (Ta-
ble 1). We presume that the testosterone values in these 
patients are due to a mixture of both, residual enzymatic 
activity	of	17β-HSD	type	3	and	additional	conversion	of	
the	 elevated	 androstenedione	 through	17β-HSD	 type	5	
[5]. 
While the cohort is small, it seems noteworthy that all 
patients would be presumed to suffer from consecutive 
gonadal failure; patient 3 from a global testicular insuffi-
ciency because of the highly elevated FSH, and all patients 
because of the slightly elevated LH (Table 1). However, as 
disease-specific	reference	intervals	for	17β-HSD	deficien-
cy are not available, the latter interpretation is weak and 
the elevation of LH might reflect the slightly altered regu-
latory mechanisms due to the diminished testosterone 
synthesis	by	the	mutated	17β-HSD	type	3.	
Patients	3	and	4	chose	to	change	to	male	gender	or	re-
mained in the male gender. Their testosterone values are 
at a much higher range than in the 2 patients who re-
mained in the female gender initially assigned. Testoster-
one	values	of	patients	3	and	4	are	at	the	lower	end	of	the	
adult male reference range (Table 1) and in the mid-ref-
erence	intervals	for	males	at	pubertal	Tanner	stages	3–4.	
Testicular function in these 2 individuals leads to an enor-
mous surge of androstenedione with values high above 
the usual reference range and a respective conversion to 
testosterone.	Patient	4	reached	a	testicular	volume	of	15	
mL and had only slightly elevated FSH levels above the 
usual male reference range, which makes relevant sper-
matogenesis likely, although he did not consent to a se-
men analysis. Also, we do not have any information on 
spermatogenesis in patient 3 as yet.
Whether these values correspond to intrauterine tes-
tosterone synthesis and action remains elusive at this 
time. However, patient 3 was raised as a female during 
childhood	 and	 the	 genital	 appearance	 was	 judged	 un-
equivocally female at several paediatric clinical investiga-
tions. We presume that the prenatal testosterone synthe-
sis was at least not high enough to induce relevant intra-
uterine virilisation.
From these descriptions we conclude that the clinical 
course	of	46,XY	patients	with	17β-HSD	type	3	deficiency	
is indeed highly variable. Especially when a residual ac-
tivity of mutated enzymes can be presumed, a male gen-
der identity may arise despite initially female-appearing 
genitalia. Therefore, any irrevocable decision regarding 
removal of the gonads or genital surgery should be post-
poned until the patient is able to consent to these proce-
dures or is old enough to review his/her options. Fur-
Table 1. Patients’ hormone levels drawn at the given age, as well as the underlying mutation in the HSD17B3 gene 
with the estimate of enzyme activity published in the literature (see text)
Patient
1 2 3 4
Age, years 15;11 17;9 17;10 16;5
Gender at birth/puberty female/female female/female female/male male/male
LH, U/L 15 13 23.23 8.77
FSH, U/L 5.2 4.1 60.5 12.7
Testosterone,	µg/L 1.13 0.73 3.51 4.09
Androstenedione,	µg/L 8.56 3.35 10 10









Approximate enzyme activity, % 0 0 0/~15 ~20/~15
Adult	male	reference	ranges	are	as	follows:	0.4–7.0	U/L	(LH),	2.6–11.0	U/L	(FSH),	3.5–9.7	μg/L	(testosterone),	
2.06–3.75	μg/L	 (androstenedione),	 and	>0.8	 (testosterone/androstenedione	 ratio).	The	 gender	 assignment	 at	























   
   
   
   
   
   
   























Horm Res Paediatr 2017;87:354–358358
DOI: 10.1159/000453613
References
 1 Hughes IA, Houk C, Ahmed SF, Lee PA: Con-
sensus statement on management of intersex 
disorders. Arch Dis Child 2006;91: 554–563.
 2 Geissler WM, Davis DL, Wu L, Bradshaw KD, 
Patel S, Mendonca BB, Elliston KO, Wilson 
JD, Russell DW, Andersson S: Male pseudo-
hermaphroditism caused by mutations of tes-
ticular	17beta-hydroxysteroid	dehydrogenase	
3.	Nat	Genet	1994;7: 34–39.
 3 George MM, New MI, Ten S, Sultan C, Bhan-




Grumbach MM, New MI, Schwarz HP, 
Blethen SL, Mendonca BB, Bloise W, Witchel 
SF, Cutler GB, Griffin JE, Wilson JD, Russel 
DW: Molecular genetics and pathophysiology 
of	 17	 beta-hydroxysteroid	 dehydrogenase	 3	
deficiency. J Clin Endocrinol Metab 1996;81: 
130–136.
 5 Werner R, Kulle A, Sommerfeld I, Riepe FG, 
Wudy S, Hartmann MF, Merz H, Döhnert U, 
Bertelloni S, Holterhus PM, Hiort O: Testos-
terone	 synthesis	 in	 patients	 with	 17β-hy-
droxysteroid dehydrogenase 3 deficiency. Sex 
Dev 2012;6: 161–168.
	 6	 Lee	YS,	Kirk	 JMW,	Stanhope	RG,	Derek	 IJ,	
Harland S, Auchus RJ, Andersson S, Hughes 
IA:	 Phenotypic	 variability	 in	 17beta-hy-





Jong FH, Kayserili H, de Vroede MA, Otten 
BJ, Rouwé CW, Mendonca BB, Rodrigues C, 
Bode HH, De Ruiter PE, Delemarre-van de 
Waal	HA,	Drop	SL:	17β-hydroxysteroid	de-
hydrogenase deficiency: diagnosis, phenotyp-
ic variability, population genetics, and world-
wide distribution of ancient and de novo mu-
tations.	 J	 Clin	 Endocrinol	 Metab	 1999;84: 
4713–4721.
 8 Twesten W, Holterhus PM, Sippell WG, Mor-
lot M, Schumacher H, Schenk B, Hiort O: 
Clinical, endocrine, and molecular genetic 
findings	in	patients	with	17β-hydroxysteroid	
dehydrogenase deficiency. Horm Res 2000;53: 
26–31.
 9 Bertelloni S, Maggio MC, Federico G, Baron-
celli	G,	Hiort	O:	17beta-hydroxysteroid	dehy-
drogenase-3 deficiency: a rare endocrine 
cause of male-to-female sex reversal. Gynecol 
Endocrinol 2006;22: 488–494.
10 Bertelloni S, Balsamo A, Giordani L, Fischetto 
R, Russo G, Delvecchio M, Gennari M, Nico-
letti A, Maggio MC, Concolino D, Cavallo L, 
Cicognani A, Chiumello G, Hiort O, Baron-
celli	GI,	Faienza	MF:	17beta-hydroxysteroid	
dehydrogenase-3 deficiency: from pregnancy 
to adolescence. J Endocrinol Invest 2009;32: 
666–670.
11 Holterhus PM, Piefke S, Hiort O: Anabolic 
steroids, testosterone-precursors and viriliz-
ing androgens induce distinct activation pro-
files of androgen responsive promoter con-
structs. J Steroid Biochem Mol Biol 2002;82: 
269–275.
12 Rösler A, Silverstein S, Abeliovich D: A 
(R80Q)	mutation	in	the	17	beta-hydroxyster-
oid dehydrogenase type 3 gene among Arabs 
of Israel is associated with pseudohermaph-
roditism in males and normal asymptomatic 
females. J Clin Endocrinol Metab 1996;81: 
1827–1831.
13	 Rosler	A:	17	beta-hydroxysteroid	dehydroge-
nase 3 deficiency in the Mediterranean popu-
lation. Pediatr Endocrinol Rev 2006;3(suppl 3): 
455–461.
14	 Hochberg	Z,	Chayen	R,	Reis	N,	Falik	Z,	Mack-
ler A, Monitzur M, Ohana N, Hiort O: Clini-
cal and genetic findings in male and female 
patients	with	5α-reductase	deficiency.	J	Clin	
Endocrinol Metab 1996;81: 2821–2827.
15	 Cohen-Kettenis	PT:	Gender	change	in	46,XY	




male or ambiguous external genitalia at birth 
due	 to	 androgen	 insensitivity	 syndrome,	 5α- 
reductase-2	deficiency,	or	17β-hydroxy	steroid	
dehydrogenase deficiency: a review of quality of 
life outcomes. Int J Pediatr Endocrinol 2009, 
DOI:	10.1155/2009/567430.
17	 Hiort	O,	Reinecke	S,	Thyen	U,	Jürgensen	M,	
Holterhus PM, Schön D, Richter-Appelt H: 
Aspects of puberty in disorders of somato-
sexual differentiation. J Pediatr Endoc Met 
2003;16: 297–306.
18 Jurgensen M, Hampel E, Hiort O, Thyen U: 
Any decision better than none: decision-mak-
ing	about	sex	of	rearing	for	siblings	with	17be-
ta-hydroxysteroid dehydrogenase-3 deficien-
cy. Arch Sex Behav 2006;35: 359–371.
19 Kulle AE, Riepe FG, Melchior D, Hiort O, 
Holterhus PM: A novel ultrapressure liquid 
chromatography tandem mass spectrometry 
method for the simultaneous determination 
of androstenedione, testosterone, and dihy-
drotestosterone in pediatric blood samples: 
age- and sex-specific reference data. J Clin En-
docrinol Metab 2010;95: 2399–2409.
20 Moghrabi N, Hughes IA, Dunaif A, Anders-
son S: Deleterious missense mutations and 
silent	 polymorphism	 in	 the	 human	 17be- 
ta-hydroxysteroid dehydrogenase 3 gene 
(HSD17B3).	 J	Clin	 Endocrinol	Metab	 1998; 
83: 2855–2860.




teroid dehydrogenase type 3 deficiency. J Ste-
roid Biochem Mol Biol 2016, DOI: 10.1016/ 
j.jsbmb.2016.05.002.
22 Ahmed SF, Iqbal A, Hughes IA: The testoste-
rone:androstendione ratio in male undermas-
culinization. Clin Endocrinol 2000;53: 697–702.
23 Bertelloni S, Dati E, Hiort O: Diagnosis of 
17beta-hydroxysteroid	 dehydrogenase	 defi-
ciency. Expert Rev Endocrinol Metab 2009; 4: 
53–65.
thermore,	 some	patients	with	17β-HSD	deficiency	may	
have testicular functions enabling them to synthesize tes-
tosterone amounts comparable to normal males, there- 
by not necessitating any hormone substitution in ado-
lescence and adulthood, and may even be fertile. Long-
term outcome studies of these conditions are desperately 
needed.
Acknowledgement
The authors are participants of the COST (European Coopera-
tion of Science and Technology) Action BM1303 DSDnet. Fund-
ing of these studies is in part possible through intramural funding 
of the University of Lübeck (SPP “Medical Genetics”).
Disclosure Statement























   
   
   
   
   
   
   
   
  
13
4.
24
5.
6.
66
 -
 1
2/
1/
20
21
 1
0:
11
:4
0 
A
M
